Financhill
Sell
41

SAVA Quote, Financials, Valuation and Earnings

Last price:
$3.33
Seasonality move :
28.64%
Day range:
$3.06 - $3.35
52-week range:
$1.15 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.97x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
12.54%
Market cap:
$160.4M
Revenue:
--
EPS (TTM):
-$2.20

Analysts' Opinion

  • Consensus Rating
    Cassava Sciences, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $8.00, Cassava Sciences, Inc. has an estimated upside of 140.96% from its current price of $3.32.
  • Price Target Downside
    According to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $3.32.

Fair Value

  • According to the consensus of 1 analyst, Cassava Sciences, Inc. has 140.96% upside to fair value with a price target of $8.00 per share.

SAVA vs. S&P 500

  • Over the past 5 trading days, Cassava Sciences, Inc. has underperformed the S&P 500 by -2.18% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Cassava Sciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Cassava Sciences, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Cassava Sciences, Inc. reported revenues of --.

Earnings Growth

  • Cassava Sciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cassava Sciences, Inc. reported earnings per share of -$0.22.
Enterprise value:
54.3M
EV / Invested capital:
0.67x
Price / LTM sales:
2.69x
EV / EBIT:
--
EV / Revenue:
-0.13x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-0.65x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$880K
Return On Assets:
-67.34%
Net Income Margin (TTM):
--
Return On Equity:
-86.98%
Return On Invested Capital:
-86.98%
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -$1.6M -$1.2M -$880K -$260K -$200K
Operating Income -$104.1M -$141.6M -$111.3M -$31.7M -$11.9M
EBITDA -$102.5M -$140.4M -$110.4M -$31.5M -$11.7M
Diluted EPS -$2.29 -$1.37 -$2.20 -$0.58 -$0.22
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $251.9M $183.3M $150.2M $202.5M $108.9M
Total Assets $274.2M $207.3M $172.5M $223.8M $129.7M
Current Liabilities $6.3M $8.3M $17.4M $57M $48M
Total Liabilities $6.7M $8.6M $17.4M $57.1M $48.2M
Total Equity $267.6M $198.7M $155.1M $166.6M $81.6M
Total Debt $259K $62K -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$81M -$78M -$83.8M -$18.3M -$6.2M
Cash From Investing -$38K -$87K -$137K -$17K -$80K
Cash From Financing $48.8M $124.7M $1M -- --
Free Cash Flow -$81.1M -$78.1M -$83.9M -$18.3M -$6.3M
SAVA
Sector
Market Cap
$160.4M
$28.4M
Price % of 52-Week High
66.67%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-0.72%
-1.32%
1-Year Price Total Return
12.54%
-22.19%
Beta (5-Year)
-1.081
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $3.12
200-day SMA
Buy
Level $2.42
Bollinger Bands (100)
Buy
Level 2.16 - 3.52
Chaikin Money Flow
Buy
Level 2.9M
20-day SMA
Buy
Level $2.99
Relative Strength Index (RSI14)
Buy
Level 54.83
ADX Line
Buy
Level 16.35
Williams %R
Sell
Level -15.3846
50-day SMA
Sell
Level $3.39
MACD (12, 26)
Buy
Level 0.03
25-day Aroon Oscillator
Sell
Level -60
On Balance Volume
Neutral
Level 11.9M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-0.0499)
Sell
CA Score (Annual)
Level (-2.9699)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.25)
--
Piotroski F Score (Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Stock Forecast FAQ

In the current month, SAVA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SAVA average analyst price target in the past 3 months is $8.00.

  • Where Will Cassava Sciences, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Cassava Sciences, Inc. share price will rise to $8.00 per share over the next 12 months.

  • What Do Analysts Say About Cassava Sciences, Inc.?

    Analysts are divided on their view about Cassava Sciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cassava Sciences, Inc. is a Sell and believe this share price will drop from its current level to $8.00.

  • What Is Cassava Sciences, Inc.'s Price Target?

    The price target for Cassava Sciences, Inc. over the next 1-year time period is forecast to be $8.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SAVA A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Cassava Sciences, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of SAVA?

    You can purchase shares of Cassava Sciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cassava Sciences, Inc. shares.

  • What Is The Cassava Sciences, Inc. Share Price Today?

    Cassava Sciences, Inc. was last trading at $3.33 per share. This represents the most recent stock quote for Cassava Sciences, Inc.. Yesterday, Cassava Sciences, Inc. closed at $3.32 per share.

  • How To Buy Cassava Sciences, Inc. Stock Online?

    In order to purchase Cassava Sciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 62x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
63
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 40x

Alerts

Buy
54
SMX alert for Dec 5

SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.

Sell
15
HOV alert for Dec 5

Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.

Buy
67
NUTX alert for Dec 5

Nutex Health, Inc. [NUTX] is up 18.9% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock